17 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend … and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend … and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend … and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:30pm
affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend … patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to any
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:28pm
events are not product- related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover … rights;
the recruitment or departure of key personnel;
the level of expenses related to any of our current or future lead compounds or clinical
DRS/A
fvazg5a
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next